延安必康(002411.SZ)孫公司新增經營範圍 涉及全系列醫用口罩的第二類醫療器械
格隆匯2月6日丨延安必康(002411.SZ)公佈,公司於2020年2月6日接到全資孫公司必康製藥新沂集團控股有限公司(“必康新沂”)的通知,為響應國家和地方政府號召,以實際行動支持新型冠狀病毒的防疫工作,必康新沂作為口罩等疫控防護產品生產線項目投資建設主體,對其經營範圍進行了變更。
近日,必康新沂完成工商變更登記,並領取了新沂市行政審批局換髮的《營業執照》。《營業執照》所載信息中經營範圍新增了“第二類醫療器械生產;第二類醫療器械批發;第二類醫療器械零售”。第二類醫療器械包括全系列醫用口罩,如醫護級口罩、N95口罩、外科手術口罩等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.